BMS Signs an Exclusive Option to License Agreement with Dragonfly Therapeutics to Develop Novel Therapies for Multiple Sclerosis and Neuro-inflammation Targets
Shots:
- Dragonfly to receive $55M upfront- additional payments for development- regulatory and sales milestones plus royalties on sales of approved products. BMS to get exclusive option to license exclusive worldwide IPR for multiple candidates developed using Dragonfly's platform for multiple new targets
- The focus of the agreement is to expand the collaboration b/w the companies from oncology and autoimmune diseases to develop drug candidates against multiple targets including multiple sclerosis and neuroinflammation
- Dragonfly’s TriNKET technology immunotherapy provides the active connection between cancer cells- and cells of the immune system including NK cells- T cells- B cells that help attack and kill cancer
Click here to read full press release/ article
Ref: PRNewswire | Image: BMS
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com